(MedPage Today) — The FDA granted accelerated approval to the first cereblon E3 ligase modulation (CELMoD) therapy for relapsed or refractory multiple myeloma, the agency announced on Thursday.
An oral drug, iberdomide (Zenbexus) is approved…
Source link
Ad Banner
Show Comments (0)
Hide Comments (0)
Subscribe
Login
0 Comments
Oldest
